TiumBio CEO On Successful Partnerships, Ambitions To Develop The Next Afstyla
Multiple Clinical Assets Progressing
Executive Summary
TiumBio’s CEO shares his experiences as the original developer of hemophilia therapy Afstyla, the reason the rare disease-specialized company is exploring opportunities in Australia, as well as its R&D plans.
You may also be interested in...
Deal Watch: Denali Partners With Sirion To Take On The Blood-Brain Barrier
Denali will collaborate with Sirion in Parkinson’s and Alzheimer’s diseases. Meanwhile, Lundbeck and Elevian unveil drug development partnerships with technology firms at the J.P. Morgan meeting.
Korea Regulatory Streamlining Plans Eye Innovation, Commercialization Support
South Korea's drug ministry, together with consumer and business groups, announces a raft of major regulatory innovation tasks it aims to achieve over the next few years, a major goal being to speed up patient access to innovation.
Asia Deal Watch: Hansoh, TiumBio Join Forces On Endometriosis Drug In Greater China
Plus deals involving Shionogi/ Grünenthal, CR Biopharma/ImmVira, Elevation Oncology/CSPC, Everest Medicines/TTY Biopharm and Dr. Reddy’s/Slayback